Showing results (191-200 of 280) with videos related to

Sort By:
Pageof 28
Leukemia|July 20, 2024
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomesJohann-Christoph Jann, Christopher B Hergott, Marisa Winkler, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell diseaseJames E Bradner, Raymond Mak, Shyam K Tanguturi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and DecitabineEvan C Chen, Yiwen Liu, Hayden L Bell, et al.
The Journal of Experimental Medicine|June 22, 2016
Targeting MTHFD2 in acute myeloid leukemiaYana Pikman, Alexandre Puissant, Gabriela Alexe, et al.
Cell Stem Cell|February 23, 2021
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative NeoplasmsDebra Van Egeren, Javier Escabi, Maximilian Nguyen, et al.
American Journal of Hematology|December 25, 2015
Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remissionMatthew D Seftel, Donna Neuberg, Mei-Jie Zhang, et al.
Blood|December 24, 2013
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemiaErika K Keeton, Kristen McEachern, Keith S Dillman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 26, 2019
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular TherapyZachariah DeFilipp, Anjali S Advani, Veronika Bachanova, et al.
Cancer Cell|October 6, 2009
Proteomic and genetic approaches identify Syk as an AML targetCynthia K Hahn, Jacob E Berchuck, Kenneth N Ross, et al.
The Journal of Clinical Investigation|February 14, 2012
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemiaVersha Banerji, Stacey M Frumm, Kenneth N Ross, et al.
Pageof 28